APP Pharmaceuticals Inc, a subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc (NASDAQ:APCVZ), said on Tuesday that it has received clearance from the US Food and Drug Administration (FDA) to market preservative-free Heparin Lock Flush Solution, USP in two dosage strengths, 10 USP Units/1 mL and 100 USP Units/1 mL.
This approval provides healthcare professionals with the only preservative-free Heparin Lock Flush Solution in a single dose vial, the company said.
Heparin Lock Flush Solution, USP is intended to maintain patency of an indwelling venipuncture device designed for intermittent injection or infusion therapy or blood sampling.